CEO: Dr. Harry E. Gruber.

Revenue: Pre-revenue.

No. of local employees: 38.

Investors: Privately funded.

Headquarters: San Diego.

Year founded: 2007.

Company description: Tocagen Inc. is a clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene transfer products for the treatment of cancer.

Key factors for success: The company is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist. Toca 511 and Toca FC, the company’s lead investigational combination product, is being evaluated in clinical trials in patients with recurrent high grade glioma (such as glioblastoma multiforme).

An investigational treatment for recurrent brain cancer developed by San Diego-based Tocagen Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99